BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18444249)

  • 1. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
    Zehetmayer S; Bauer P; Posch M
    Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis.
    Liu P; Hwang JT
    Bioinformatics; 2007 Mar; 23(6):739-46. PubMed ID: 17237060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-stage designs for experiments with a large number of hypotheses.
    Zehetmayer S; Bauer P; Posch M
    Bioinformatics; 2005 Oct; 21(19):3771-7. PubMed ID: 16091414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives.
    van der Laan MJ; Dudoit S; Pollard KS
    Stat Appl Genet Mol Biol; 2004; 3():Article15. PubMed ID: 16646793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False discovery rate control in two-stage designs.
    Zehetmayer S; Posch M
    BMC Bioinformatics; 2012 May; 13():81. PubMed ID: 22559038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method to increase the power of multiple testing procedures through sample splitting.
    Rubin D; Dudoit S; van der Laan M
    Stat Appl Genet Mol Biol; 2006; 5():Article19. PubMed ID: 17049030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fallback procedure for evaluating a single family of hypotheses.
    Wiens BL; Dmitrienko A
    J Biopharm Stat; 2005; 15(6):929-42. PubMed ID: 16279352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple testing. Part I. Single-step procedures for control of general type I error rates.
    Dudoit S; van der Laan MJ; Pollard KS
    Stat Appl Genet Mol Biol; 2004; 3():Article13. PubMed ID: 16646791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative trait Loci analysis using the false discovery rate.
    Benjamini Y; Yekutieli D
    Genetics; 2005 Oct; 171(2):783-90. PubMed ID: 15956674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
    Lai TL; Shih MC; Zhu G
    Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of experiments with adaptive interim analyses.
    Bauer P; Köhne K
    Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDR-controlling testing procedures and sample size determination for microarrays.
    Li SS; Bigler J; Lampe JW; Potter JD; Feng Z
    Stat Med; 2005 Aug; 24(15):2267-80. PubMed ID: 15977294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.